|
humans |
22 |
|
female |
21 |
|
adolescent |
17 |
|
middle aged |
16 |
|
ovarian cancer |
16 |
|
adult |
15 |
|
aged |
15 |
|
endometrial carcinoma |
14 |
|
prognosis |
14 |
|
aged, 80 and over |
12 |
|
immunohistochemistry |
11 |
|
risk factors |
11 |
|
cervical cancer |
10 |
|
chemotherapy |
10 |
|
male |
10 |
|
colposcopy |
9 |
|
diagnosis, differential |
9 |
|
animals |
8 |
|
ascitic fluid |
8 |
|
carcinoma/metabolism |
8 |
|
carcinoma/secondary |
8 |
|
cell adhesion |
8 |
|
follow-up studies |
8 |
|
hepatitis b, chronic - complications - diagnosis |
8 |
|
human papillomavirus |
8 |
|
liver cirrhosis - complications - diagnosis |
8 |
|
models, biological |
8 |
|
predictive value of tests |
8 |
|
reproducibility of results |
8 |
|
accuracy |
7 |
|
alanine aminotransferase blood level |
7 |
|
alanine transaminase - metabolism |
7 |
|
antiviral therapy |
7 |
|
cervical intraepithelial neoplasia |
7 |
|
chemoresistance |
7 |
|
choriocarcinoma |
7 |
|
diagnostic biomarker |
7 |
|
diagnostic test accuracy study |
7 |
|
disease severity |
7 |
|
epithelioid |
7 |
|
gene expression regulation, neoplastic |
7 |
|
genes, tumor suppressor |
7 |
|
gestational |
7 |
|
hepatitis b |
7 |
|
hepatitis b e antigens - metabolism |
7 |
|
hepatitis b, chronic - enzymology - pathology |
7 |
|
hydatidiform mole |
7 |
|
iaspp |
7 |
|
leiomyosarcoma |
7 |
|
liver cirrhosis - enzymology - pathology |
7 |
|
microrna |
7 |
|
neoadjuvant chemotherapy |
7 |
|
neoplasm staging |
7 |
|
ovarian clear cell carcinoma |
7 |
|
plk1 |
7 |
|
pregnancy |
7 |
|
reverse transcriptase polymerase chain reaction |
7 |
|
sensitivity and specificity |
7 |
|
trophoblastic |
7 |
|
tumor markers, biological - analysis |
7 |
|
tumors |
7 |
|
asian continental ancestry group - statistics & numerical data |
6 |
|
c-mos |
6 |
|
carcinoma, hepatocellular - ethnology - pathology - virology |
6 |
|
cervical smear |
6 |
|
checkpoint inhibitor |
6 |
|
child |
6 |
|
child, preschool |
6 |
|
circular dna |
6 |
|
diffusion-weighted imaging |
6 |
|
dna methylation |
6 |
|
dna, viral - blood |
6 |
|
gastroenterology |
6 |
|
genital neoplasms, female - metabolism - pathology |
6 |
|
germ cell tumor |
6 |
|
gestational trophoblastic disease |
6 |
|
gestational trophoblastic disease - metabolism - pathology |
6 |
|
gynecological neoplasm |
6 |
|
hepatitis b antibodies - blood |
6 |
|
hepatitis b surface antigens - immunology |
6 |
|
hepatitis b virus |
6 |
|
hepatitis b virus - genetics - immunology - isolation & purification |
6 |
|
hepatitis b, chronic - ethnology - immunology - pathology |
6 |
|
hong kong - epidemiology |
6 |
|
immunotherapy |
6 |
|
infant |
6 |
|
liver - pathology - virology |
6 |
|
liver biopsy |
6 |
|
liver cirrhosis - ethnology - pathology - virology |
6 |
|
liver neoplasms - ethnology - pathology - virology |
6 |
|
longitudinal studies |
6 |
|
lymphadenectomy |
6 |
|
magnetic resonance imaging |
6 |
|
malignant ovarian germ cell tumors |
6 |
|
medical sciences |
6 |
|
neoplasms |
6 |
|
ovarian carcinoma |
6 |
|
placenta - metabolism |
6 |
|
proto-oncogene proteins c-mos - biosynthesis |
6 |
|
response to therapy |
6 |
|
screening |
6 |
|
seroepidemiologic studies |
6 |
|
viral hepatitis |
6 |
|
virus replication |
6 |
|
adenocarcinoma, clear cell - genetics - metabolism - pathology |
5 |
|
adhesion |
5 |
|
antimetabolites, antineoplastic - pharmacology |
5 |
|
azacitidine - analogs & derivatives - pharmacology |
5 |
|
biopsy, needle |
5 |
|
carcinoma, endometrioid - enzymology - genetics |
5 |
|
carcinoma, endometrioid - enzymology - genetics - pathology |
5 |
|
carcinoma, endometrioid - genetics - metabolism - pathology |
5 |
|
case-control studies |
5 |
|
cell cycle proteins |
5 |
|
cell cycle proteins - analysis |
5 |
|
cell proliferation |
5 |
|
cervical intra-epithelial neoplasia |
5 |
|
chemoradiotherapy |
5 |
|
clear cell |
5 |
|
cp: cancer |
5 |
|
cp: metabolism |
5 |
|
cpg islands |
5 |
|
cystadenocarcinoma, mucinous - genetics - metabolism - pathology |
5 |
|
cystadenocarcinoma, serous - genetics - metabolism - pathology |
5 |
|
diffusion magnetic resonance imaging |
5 |
|
dna mutational analysis |
5 |
|
dna replication |
5 |
|
dna, neoplasm - chemistry - genetics - metabolism |
5 |
|
dna-binding proteins |
5 |
|
dna-binding proteins - analysis |
5 |
|
endometrial neoplasms - enzymology - genetics |
5 |
|
endometrial neoplasms - enzymology - genetics - pathology |
5 |
|
endometrial neoplasms - metabolism - pathology |
5 |
|
gene frequency |
5 |
|
genetic predisposition to disease - genetics |
5 |
|
genotype |
5 |
|
glutathione s-transferase pi |
5 |
|
glutathione transferase - analysis - genetics - metabolism |
5 |
|
glutathione transferase - genetics |
5 |
|
glycolysis |
5 |
|
immunoenzyme techniques |
5 |
|
intracellular signaling peptides and proteins |
5 |
|
isoenzymes - genetics |
5 |
|
ki-67 antigen - analysis |
5 |
|
ki67 |
5 |
|
leiomyoma |
5 |
|
leiomyoma with bizarre nuclei |
5 |
|
lipogenesis |
5 |
|
loss of heterozygosity |
5 |
|
mechanotransduction |
5 |
|
metabolic reprogramming |
5 |
|
minichromosome maintenance protein 7 (mcm7) |
5 |
|
multivariate analysis |
5 |
|
mutation - genetics |
5 |
|
nuclear proteins |
5 |
|
nuclear proteins - analysis |
5 |
|
observer variation |
5 |
|
ovarian neoplasms - genetics - metabolism - pathology |
5 |
|
ovary - metabolism - pathology |
5 |
|
p-cadherin |
5 |
|
peritoneal metastasis |
5 |
|
phosphohistone-h3 |
5 |
|
polymerase chain reaction |
5 |
|
polymorphism, restriction fragment length |
5 |
|
polymorphism, single nucleotide |
5 |
|
proliferation |
5 |
|
promoter regions, genetic - genetics |
5 |
|
proteins - genetics |
5 |
|
random cervical biopsy |
5 |
|
rna, messenger - genetics - metabolism |
5 |
|
smooth muscle tumour of uncertain malignant potential |
5 |
|
survival analysis |
5 |
|
tissue array analysis |
5 |
|
tissue microarray |
5 |
|
tumor cells, cultured |
5 |
|
tumor mesothelium |
5 |
|
tumor suppressor proteins |
5 |
|
uterine cervical neoplasms |
5 |
|
uterus |
5 |
|
2-[18f]fdg pet/ct |
4 |
|
apoptosis |
4 |
|
asian continental ancestry group - genetics |
4 |
|
atypical leiomyoma |
4 |
|
autophagy |
4 |
|
autophagy and chemoresistance |
4 |
|
b-catenin |
4 |
|
beta catenin - metabolism |
4 |
|
brca1 |
4 |
|
brca1 protein - genetics |
4 |
|
breast cancer |
4 |
|
breast neoplasms - genetics |
4 |
|
cell differentiation |
4 |
|
cell line, tumor |
4 |
|
chemotherapy response score |
4 |
|
china |
4 |
|
chinese |
4 |
|
compliance |
4 |
|
congenital fibrosarcoma |
4 |
|
contrast-enhanced ct |
4 |
|
endometrial cancers |
4 |
|
endometrial neoplasms - genetics - metabolism - pathology |
4 |
|
endometrial neoplasms - pathology - physiopathology |
4 |
|
follistatin-related proteins - genetics - physiology |
4 |
|
gli1 |
4 |
|
hedgehog proteins - metabolism |
4 |
|
immunohistochemical staining |
4 |
|
intestinal |
4 |
|
metastasis |
4 |
|
microsatellite instability analysis |
4 |
|
mismatch repair deficiency |
4 |
|
mutation |
4 |
|
neoplasm invasiveness |
4 |
|
ovarian neoplasms - genetics |
4 |
|
ovarian neoplasms - metabolism - pathology |
4 |
|
ovarian neoplasms - pathology - physiopathology |
4 |
|
ovary |
4 |
|
prediction model |
4 |
|
primary care |
4 |
|
rare tumor |
4 |
|
receptors, cell surface - metabolism |
4 |
|
signal transduction |
4 |
|
signal transduction - physiology |
4 |
|
somatic mutations |
4 |
|
stump |
4 |
|
transcription factors - metabolism |
4 |
|
uterine leiomyosarcoma |
4 |
|
venous thromboembolism |
4 |
|
adenocarcinoma |
3 |
|
adenocarcinoma, clear cell - drug therapy - pathology - radiotherapy |
3 |
|
adenocarcinoma, clear cell - pathology - therapy |
3 |
|
antifibrinolytic agents - adverse effects |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
3 |
|
area under the curve |
3 |
|
arias-stella reactionclear |
3 |
|
aspiration biopsy |
3 |
|
aspiration cytology, fine-needle |
3 |
|
biopsy, fine-needle |
3 |
|
brachytherapy - methods |
3 |
|
cancer stem cells |
3 |
|
cell carcinoma |
3 |
|
cell nucleus |
3 |
|
cervical carcinoma |
3 |
|
chemoirradiation |
3 |
|
choriocarcinoma, non-gestational - pathology - therapy |
3 |
|
clear cell adenocarcinoma |
3 |
|
clear cell carcinoma |
3 |
|
cobas |
3 |
|
combined modality therapy |
3 |
|
cytoreduction |
3 |
|
dendrimer |
3 |
|
dendritic cells, follicular - pathology |
3 |
|
diffusion kurtosis imaging |
3 |
|
disease staging |
3 |
|
early infarct |
3 |
|
endometrial hyperplasia |
3 |
|
endometrial polyps |
3 |
|
entropy |
3 |
|
ependymoma |
3 |
|
estrogen receptors |
3 |
|
fdg |
3 |
|
figo |
3 |
|
gemcitabine |
3 |
|
glioma - pathology |
3 |
|
gynecologic surgical procedures |
3 |
|
hematologic neoplasms - pathology |
3 |
|
histologic subtypes |
3 |
|
histopathologic features |
3 |
|
hnf-1β |
3 |
|
hpv test |
3 |
|
infarction - chemically induced - pathology |
3 |
|
leiomyoma - complications - drug therapy - pathology |
3 |
|
liver - pathology |
3 |
|
liver diseases - etiology - pathology |
3 |
|
lymph nodes - pathology |
3 |
|
medical sciences biology |
3 |
|
menorrhagia |
3 |
|
menorrhagia - drug therapy - etiology - pathology |
3 |
|
myxopapillary |
3 |
|
nanovector |
3 |
|
napsin a |
3 |
|
necrosis |
3 |
|
neoplasm invasiveness - pathology |
3 |
|
neoplasm recurrence, local |
3 |
|
nongestatational choriocarcinoma |
3 |
|
onclarity |
3 |
|
ovarian neoplasms - pathology - therapy |
3 |
|
paclitaxel |
3 |
|
pet/ct |
3 |
|
pipelle endometrial sampler |
3 |
|
primary screening |
3 |
|
rare diseases |
3 |
|
recurrence detection |
3 |
|
reishi |
3 |
|
risk assessment |
3 |
|
sacrococcygeal region |
3 |
|
sarcoma - pathology |
3 |
|
sarcoma, follicular dendritic cell |
3 |
|
smooth muscle tumor |
3 |
|
soft tissue neoplasms - pathology |
3 |
|
squamous cell carcinoma |
3 |
|
submandibular gland - pathology |
3 |
|
synthetic magnetic resonance imaging |
3 |
|
targeted therapy |
3 |
|
thrombosis - chemically induced - pathology |
3 |
|
tranexamic acid |
3 |
|
tranexamic acid - adverse effects |
3 |
|
treatment outcome |
3 |
|
uterine cervical neoplasms - drug therapy - pathology - radiotherapy |
3 |
|
uterine neoplasms - complications - drug therapy - pathology |
3 |
|
adenocarcinoma in situ |
2 |
|
alk |
2 |
|
anaplastic large cell lymphoma (alcl) |
2 |
|
angiogenesis |
2 |
|
angioimmunoblastic |
2 |
|
antigens, cd - analysis |
2 |
|
antigens, differentiation, myelomonocytic - analysis |
2 |
|
aptima hpv |
2 |
|
ascites cell |
2 |
|
aspergillosis - complications - diagnosis |
2 |
|
assisted reproduction |
2 |
|
atrx |
2 |
|
automated dna-image-cytometry |
2 |
|
biomarkers |
2 |
|
brain diseases - complications - diagnosis |
2 |
|
cancer associated fibroblast |
2 |
|
carcinoma |
2 |
|
carcinoma - pathology |
2 |
|
carcinoma, papillary - pathology - ultrastructure |
2 |
|
carcinoma, renal cell - pathology - ultrastructure |
2 |
|
cd30 |
2 |
|
cdc16 |
2 |
|
cell component |
2 |
|
cellular leiomyoma |
2 |
|
cervical adenocarcinoma |
2 |
|
children |
2 |
|
clinical article |
2 |
|
cobas hpv |
2 |
|
cotelydonoid dissecting leiomyoma |
2 |
|
cyclin-dependent kinase inhibitor p16 - biosynthesis |
2 |
|
cystadenocarcinoma, mucinous - metabolism - pathology |
2 |
|
cytology |
2 |
|
daxx |
2 |
|
depdc1b |
2 |
|
dissecting leiomyoma |
2 |
|
dna ploidy |
2 |
|
ectopic pregnancy |
2 |
|
endometrial stromal sarcoma |
2 |
|
endometrioid |
2 |
|
endometrioid with clear cells |
2 |
|
endometriosis |
2 |
|
epithelial mesenchymal transition |
2 |
|
epithelial- myoepithelial carcinoma |
2 |
|
epithelioid leiomyoma |
2 |
|
epithelioid leiomyosarcoma |
2 |
|
exaggerated placental site |
2 |
|
fatal outcome |
2 |
|
female genital tract |
2 |
|
fine-needle aspiration |
2 |
|
glucocorticoids - therapeutic use |
2 |
|
gonadotropin-releasing hormone analog |
2 |
|
history, 16th century |
2 |
|
hpv |
2 |
|
hpv dna test |
2 |
|
iatrogenic lesions |
2 |
|
immunoblastic lymphadenopathy - genetics - pathology |
2 |
|
infancy |
2 |
|
infarct type necrosis |
2 |
|
keratin-7 |
2 |
|
keratins - analysis |
2 |
|
kidney neoplasms - pathology - ultrastructure |
2 |
|
lymphoma, large b-cell, diffuse - immunology - pathology |
2 |
|
lymphoma, t-cell - genetics - pathology |
2 |
|
melanoma |
2 |
|
mitotically active leiomyoma |
2 |
|
molecular classification |
2 |
|
myxoid leiomyoma |
2 |
|
myxoid leiomyosarcoma |
2 |
|
neoplasm recurrence, local - epidemiology - pathology |
2 |
|
ophthalmoplegia - drug therapy - etiology |
2 |
|
orbital pseudotumor - diagnosis |
2 |
|
osteosarcoma - pathology |
2 |
|
p16 |
2 |
|
p53 |
2 |
|
patient outcomes |
2 |
|
peutz jeghers syndrome |
2 |
|
placental site nodule/plaque |
2 |
|
predictors |
2 |
|
prednisolone - therapeutic use |
2 |
|
premenarche |
2 |
|
protein-tyrosine kinases - analysis - immunology |
2 |
|
receptor protein-tyrosine kinases |
2 |
|
receptors, estrogen - biosynthesis |
2 |
|
receptors, progesterone - biosynthesis |
2 |
|
retroperitoneal neoplasms - metabolism - pathology |
2 |
|
retrospective studies |
2 |
|
salivary gland neoplasms - pathology |
2 |
|
salivary gland neoplasms aspiration biopsy |
2 |
|
scube3 |
2 |
|
serous borderline |
2 |
|
sil |
2 |
|
smooth muscle tumor - metabolism - pathology - surgery |
2 |
|
smooth muscle tumor of low malignant potential |
2 |
|
squamous intraepithelial lesion |
2 |
|
steroid cell tumor |
2 |
|
steroid cell tumor not otherwise specified |
2 |
|
t-cell lymphoma |
2 |
|
tamoxifen |
2 |
|
telomere maintenance mechanism |
2 |
|
tumor suppressor protein p53 - biosynthesis |
2 |
|
ubiquitin-protein ligases - biosynthesis |
2 |
|
uterine cervix |
2 |
|
uterine leiomyoma |
2 |
|
uterine neoplasms - metabolism - pathology - surgery |
2 |
|
uterine smooth muscle tumor of uncertain malignant potential |
2 |
|
uterine smooth muscle tumor of uncertain malignant potential (stump) |
2 |
|
uterine smooth muscle tumour of uncertain malignant potential |
2 |
|
vagina |
2 |
|
vaginal squamous intraepithelial neoplasia |
2 |
|
vain |
2 |
|
ameloblastoma |
1 |
|
arias-stella reaction |
1 |
|
artificial intelligence |
1 |
|
cancer |
1 |
|
cardiff |
1 |
|
caucasian |
1 |
|
cd34 |
1 |
|
comparison |
1 |
|
deep learning |
1 |
|
endometrial polyp |
1 |
|
endometrium |
1 |
|
esophagus |
1 |
|
follicular dendritic cell tumor |
1 |
|
gastrointestinal autonomic nerve tumor |
1 |
|
guidelines |
1 |
|
hong kong |
1 |
|
incidence |
1 |
|
inflammatory fibrosarcoma |
1 |
|
inflammatory pseudotumor |
1 |
|
isgyp |
1 |
|
lehman and hart |
1 |
|
molecular pathology |
1 |
|
mucinous |
1 |
|
mucinous hyperplasia |
1 |
|
mucinous metaplasia |
1 |
|
mullerian adenosarcoma |
1 |
|
papillary carcinoma |
1 |
|
papillary endometrial hyperplasia |
1 |
|
papillary proliferation |
1 |
|
pathology |
1 |
|
pulmonary embolism |
1 |
|
quality assurance |
1 |
|
recurrence |
1 |
|
stomach |
1 |
|
stromal tumor |
1 |
|
ultrastructure |
1 |
|
wales |
1 |
